- Home
- MDRR vs NRXP Comparison
MDRR vs NRXP Comparison
Compare MDRR & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDRR
- NRXP
- Stock Information
- Founded
- MDRR 2015
- NRXP 2015
- Country
- MDRR United States
- NRXP United States
- Employees
- MDRR N/A
- NRXP N/A
- Industry
- MDRR Real Estate Investment Trusts
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- MDRR Real Estate
- NRXP Health Care
- Exchange
- MDRR Nasdaq
- NRXP Nasdaq
- Market Cap
- MDRR 13.4M
- NRXP 14.8M
- IPO Year
- MDRR 2018
- NRXP N/A
- Fundamental
- Price
- MDRR $12.40
- NRXP $1.23
- Analyst Decision
- MDRR
- NRXP Strong Buy
- Analyst Count
- MDRR 0
- NRXP 3
- Target Price
- MDRR N/A
- NRXP $31.33
- AVG Volume (30 Days)
- MDRR 4.7K
- NRXP 160.5K
- Earning Date
- MDRR 11-12-2024
- NRXP 11-14-2024
- Dividend Yield
- MDRR 1.94%
- NRXP N/A
- EPS Growth
- MDRR N/A
- NRXP N/A
- EPS
- MDRR N/A
- NRXP N/A
- Revenue
- MDRR $9,916,929.00
- NRXP N/A
- Revenue This Year
- MDRR N/A
- NRXP N/A
- Revenue Next Year
- MDRR N/A
- NRXP N/A
- P/E Ratio
- MDRR N/A
- NRXP N/A
- Revenue Growth
- MDRR N/A
- NRXP N/A
- 52 Week Low
- MDRR $8.24
- NRXP $1.10
- 52 Week High
- MDRR $14.95
- NRXP $7.33
- Technical
- Relative Strength Index (RSI)
- MDRR 57.24
- NRXP 43.63
- Support Level
- MDRR $12.09
- NRXP $1.13
- Resistance Level
- MDRR $12.38
- NRXP $1.36
- Average True Range (ATR)
- MDRR 0.15
- NRXP 0.09
- MACD
- MDRR 0.02
- NRXP 0.01
- Stochastic Oscillator
- MDRR 79.57
- NRXP 34.37
About MDRR Medalist Diversified REIT Inc.
Medalist Diversified REIT Inc is engaged in the acquisition, reposition, renovation, leasing, and managing of income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its principal objectives include sourcing value-added Investments in markets in which it maintains deep industry relationships and local market knowledge and the creation of value for stockholders by utilizing its relationships and local knowledge of commercial real estate investment, management, and disposition.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.